Table 3.
SBCE findings in patients under antiplatelet and anticoagulant drugs.
| Antiplatelet | Anticoagulant | |||||
|---|---|---|---|---|---|---|
| No | Yes | P | No | Yes | P | |
| (n = 201) | (n = 73) | (n = 230) | (n = 44) | |||
| Erosions, n (%) | 40 (19.9) | 14 (19.2) | n.s | 46 (20.0) | 8 (18.2) | n.s |
| Ulcers, n (%) | 11 (5.5) | 5 (6.8) | n.s | 12 (5.2) | 4 (9.1) | n.s |
| Angioectasias, n (%) | 39 (19.4) | 17 (23.3) | n.s | 43 (18.7) | 13 (29.5) | n.s |
| Tumors, n (%) | 7 (3.5) | 2 (2.7) | n.s | 4 (1.7) | 5 (11.4) | 0.002 |